AbbVie Inc. reported its financial results for the third quarter and the first nine months of 2025, revealing a net revenue of $15.8 billion for the quarter, a 9.1% increase from $14.5 billion in the same period last year. For the nine months ending September 30, 2025, the company achieved net revenues of $44.5 billion, up from $41.2 billion in 2024. However, net earnings attributable to AbbVie Inc. significantly decreased to $186 million, or $0.10 per diluted share, compared to $1.6 billion, or $0.88 per diluted share, in the prior year quarter. The decline in profitability was attributed to substantial costs related to acquisitions, including $2.7 billion in acquired in-process research and development (IPR&D) and milestone expenses.
The company experienced notable changes in its product portfolio, particularly in immunology, where Skyrizi and Rinvoq saw revenue increases of 46.8% and 35.3%, respectively, driven by strong market uptake. Conversely, Humira's revenues plummeted by 55.4% due to the impact of biosimilar competition following its loss of exclusivity. AbbVie’s total operating costs rose to $13.9 billion for the quarter, up from $10.6 billion a year earlier, largely due to increased expenses related to acquisitions and research and development.
Strategically, AbbVie has been active in expanding its portfolio through acquisitions, including the recent purchase of Gilgamesh Pharmaceuticals for approximately $900 million, which is expected to enhance its pipeline in treating major depressive disorder. The company also completed the acquisition of Nimble Therapeutics earlier in 2025, further diversifying its offerings in the biopharmaceutical space. AbbVie’s workforce remains robust, with approximately 55,000 employees, reflecting its commitment to innovation and growth.
Operationally, AbbVie reported cash flows from operating activities of $13.8 billion for the nine months ended September 30, 2025, an increase from $11.8 billion in the prior year. The company’s cash and equivalents stood at $5.6 billion as of September 30, 2025, slightly up from $5.5 billion at the end of 2024. AbbVie also announced a quarterly dividend increase to $1.73 per share, reflecting its ongoing commitment to returning value to shareholders despite the challenges faced in the current fiscal year.
Looking ahead, AbbVie anticipates continued growth driven by its diverse product pipeline and strategic investments in research and development. The company plans to focus on maximizing the benefits of its diversified revenue base while navigating the complexities of the global pharmaceutical market, including potential regulatory changes and competitive pressures.
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company focused on researching, developing, manufacturing, and marketing innovative therapies across immunology, oncology, aesthetics, neuroscience, and eye care. Its diverse product portfolio addresses complex diseases with leading biologics and pharmaceuticals, serving healthcare providers, payers, and patients worldwide. AbbVie’s integrated business model combines advanced R&D, global supply chain, and targeted commercialization to deliver specialized medicines and medical devices in major international markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.